Subcutaneous Amivantamab Plus Lazertinib Non-Inferior to IV Dosing in NSCLC

Unexpectedly offers a possible overall survival benefit, researchers say

Related Keywords

Toronto ,Ontario ,Canada ,United States ,Boston ,Massachusetts ,Chicago ,Illinois ,American ,Jessica Jiyeong Lin ,Mike Bassett ,Natashab Leighl ,Princess Margaret Cancer Centre ,Harvard Medical School ,American Society Of Clinical Oncology ,American Society ,Clinical Oncology ,Massachusetts General Hospital ,